Crispr Cas9 Kit
Cas9 Protein and T7 gRNA SmartNuclease Synthesis Kit |
|||
CAS400A-KIT | SBI | 1 kit (10 rxn) | EUR 1332 |
Abmgood Laboratories manufactures the crispr cas9 kit reagents distributed by Genprice. The Crispr Cas9 Kit reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact ABMgood. Other Crispr products are available in stock. Specificity: Crispr Category: Cas9 Group: Kit
Canine True insulin ELISA kit |
||
BlueGene | 48 wells plate | EUR 280 |
Dog True insulin ELISA kit |
||
BlueGene | 1 plate of 96 wells | EUR 822 |
Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Canine True insulin ELISA kit |
||
BlueGene | 96 wells plate | EUR 405 |
Canine True insulin ELISA kit |
||
BlueGene | 96T | EUR 700 |
Description: ELISA |
Porcine True insulin ELISA kit |
||
BlueGene | 96T | EUR 700 |
Description: ELISA |
Rat True insulin ELISA kit |
||
BlueGene | 96T | EUR 700 |
Description: ELISA |
Sheep True insulin ELISA kit |
||
BlueGene | 96T | EUR 700 |
Description: ELISA |
TIGIT CRISPR/Cas9 Lentivirus (Integrating) |
|||
78058 | BPS Bioscience | 500 µl x 2 | EUR 795 |
Description: TIGIT (T-cell immunoreceptor with Ig and ITIM domains; VSTM3; VSIG9) is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells and activated CD4+, CD8+, and regulatory T-cells. Interaction with the Poliovirus Receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits either the Src homology (SH) domain-containing tyrosine phosphatases SHP1 and SHP2, or the Inositol phosphatase SHIP1 and SHIP2, to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-κB and NFAT T-cell receptor (TCR) signaling, which blocks T-cell proliferation and cytokine production. TIGIT also serves as a competitive inhibitor of CD226, a costimulatory receptor for CD155. TIGIT-targeting antibodies which block this T-cell intrinsic inhibitory effect have shown enhanced anti-tumor and anti-viral functions in preclinical studies._x000D_ The TIGIT CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human TIGIT (GenBank Accession #NM_173799) driven by a U6 promoter._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest. |
NLRP3 CRISPR/Cas9 Lentivirus (Integrating) |
|||
78545 | BPS Bioscience | 500 µl x 2 | EUR 995 |
Description: NLR family Pyrin domain containing 3 (NLRP3) is expressed in macrophages and is a component of inflammasomes. NLRP3 detects uric acid and extracellular ATP in damaged tissue and interacts with a pro-apoptotic protein that recruits caspases. This complex is also an upstream activator of NF-κB signaling and triggers an immune response as part of the innate immune system. Mutations in NLRP3 are known to cause autoinflammatory and neuroinflammatory diseases, such as Alzheimer's, Parkinson's, and prion disease. The NLRP3 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human NLRP3 (Figure 1 and Table 1), allowing the knockdown of NLRP3 in transduced cells.The DNA transduced by the integrating lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiencies also depend on the cell type. |
CRISPR-Associated Endonuclease Cas9/Csn1 (Cas9) Antibody |
|||
abx340123-100ug | Abbexa | 100 ug | EUR 469.2 |
CRISPR-Associated Endonuclease Cas9/Csn1 (Cas9) Antibody |
|||
abx340123-10mg | Abbexa | 10 mg | Ask for price |
CRISPR-Associated Endonuclease Cas9/Csn1 (Cas9) Antibody |
|||
abx340123-1mg | Abbexa | 1 mg | EUR 337.5 |
FCGR2A CRISPR/Cas9 Lentivirus (Integrating) |
|||
78537 | BPS Bioscience | 500 µl x 2 | EUR 795 |
Description: Fc Gamma Receptor 2A (also known as CD32A, Fc-gamma-RIIa, FcgRIIa) is a low affinity Fc receptor for immunoglobulin G, encoded by the FCGR2A gene. Fc Gamma Receptor 2A is a cell surface receptor that is expressed on a variety of immune cells such as macrophages and neutrophils. It is involved in phagocytosis and in the clearing of spent immune complexes from the circulation. A polymorphism in FCGR2A has been associated with increased risks of nephritis and lupus.The FCGR2A CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to transduce into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human FCGR2A. |
Mouse Anti- CRISPR/Cas9 [7A9-3A3] |
|||
MBS375383-002mg | MyBiosource | 0.02mg | EUR 335 |
Mouse Anti- CRISPR/Cas9 [7A9-3A3] |
|||
MBS375383-005mg | MyBiosource | 0.05mg | EUR 485 |
Mouse Anti- CRISPR/Cas9 [7A9-3A3] |
|||
MBS375383-01mg | MyBiosource | 0.1mg | EUR 560 |
Mouse Anti- CRISPR/Cas9 [7A9-3A3] |
|||
MBS375383-5x01mg | MyBiosource | 5x0.1mg | EUR 2305 |
Kit sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K4860905 | ABM | 3 x 1.0 ug | EUR 451.2 |
KIT sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K1152305 | ABM | 3 x 1.0 ug | EUR 451.2 |
PD-1 CRISPR/Cas9 Lentivirus (Integrating) |
|||
78052 | BPS Bioscience | 500 µl x 2 | EUR 820 |
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes._x000D_ The PD-1 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human PD-1 (Programmed Cell Death 1, PDCD1, CD279, GenBank Accession #NM_005018) driven by a U6 promoter (Figures 1 and 2)._x000D_ The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_Â _x000D_ |
CRISPR Cas9 SP Rabbit Polyclonal Antibody |
|||
E10G23119 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
A-9001 | EpiGentek |
|
|
PD-L1 CRISPR/Cas9 Lentivirus (Integrating) |
|||
78057 | BPS Bioscience | 500 µl x 2 | EUR 795 |
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes._x000D_The PD-L1 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7-H1), GenBank accession #NM_021893) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ |
Kit sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
K6939006 | ABM | 1.0 ug DNA | EUR 200.4 |